erlotinib has been researched along with tariquidar in 1 studies
| Studies (erlotinib) | Trials (erlotinib) | Recent Studies (post-2010) (erlotinib) | Studies (tariquidar) | Trials (tariquidar) | Recent Studies (post-2010) (tariquidar) |
|---|---|---|---|---|---|
| 221 | 0 | 180 | 210 | 16 | 138 |
| Protein | Taxonomy | erlotinib (IC50) | tariquidar (IC50) |
|---|---|---|---|
| ATP-dependent translocase ABCB1 | Mus musculus (house mouse) | 0.0643 | |
| ATP-dependent translocase ABCB1 | Homo sapiens (human) | 1.0841 | |
| Cytochrome P450 2C9 | Homo sapiens (human) | 7.1 | |
| Broad substrate specificity ATP-binding cassette transporter ABCG2 | Homo sapiens (human) | 1.2363 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cai, Z; Ghaleb, H; Huang, W; Jiang, Y; Liu, Y; Qian, H; Qiu, Q; Shi, W; Yin, Z; Zhang, P; Zhou, J; Zou, F | 1 |
1 other study(ies) available for erlotinib and tariquidar
| Article | Year |
|---|---|
Exploration of novel phthalazinone derivatives as potential efflux transporter inhibitors for reversing multidrug resistance and improving the oral absorption of paclitaxel.
Topics: ATP Binding Cassette Transporter, Subfamily G, Member 2; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Humans; Neoplasm Proteins; Neoplasms; Paclitaxel | 2022 |